Investment Insider: Pharmaceutical industry's best years lie ahead

I have heard many experts say that the best days of the pharmaceutical sector are behind it.

Drug developers are finding it harder to come up with new medicines – it is not easy to find a new statin or cholesterol-buster to compete with existing medications. Consequently, companies are forced to go to greater lengths to find new treatments as patents expire and me-too drugs appear.

That said, big pharmas such as GlaxoSmithKline boast a bulging pipeline of drugs in late-stage development. Many of these show promise and GSK expects a slew of drugs to gain regulatory approval in the next two years.

But for now, it has been a case of managing costs and generating cash from existing products. It is also keeping shareholders sweet by hiking its dividends. A prospective dividend yield of 5 per cent is welcome when stock markets are volatile. At 1,435p the shares are valued at around 11 times earnings, which is not too demanding.

AstraZeneca is going through similar patent-expiry pains. In the first quarter, revenues fell 11 per cent after it lost exclusivity on key brands. In fact, the fall for the year is likely to be in the mid-teens and the chief executive is to retire early. The shares are valued at eight times earnings which reflects the pessimism over future profits. But, there are no indications it intends to cut its dividend.

For investors with an eye on growth, Shire's business is founded on a strategy of buying young drugs from small biotechnology outfits and developing them. This has worked well with profits more than trebling in four years. The company does pay a small dividend, but rather than ratchet up its payout, Shire prefers to plough most of its earnings back into the business.

Hikma is another highly-rated growth company. It began as a one-product outfit with a bacterial infection-fighting drug. Today, it is a £1.3bn business that has doubled its sales and profits in four years . It is a good example of a Garp – Growth At a Reasonable Price – share, with a price/earnings to growth (PEG) ratio of 0.5. Ideally, you want a PEG ratio of less than one.

David Kuo is director financial website fool.co.uk

Independent Comment
blog comments powered by Disqus
Finacial products from our partners
News in pictures
World news in pictures
Property search
       

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    Day In a Page

    James Pembroke: The man who's eaten everywhere

    The man who's eaten everywhere

    Few people know more about restaurants than James Pembroke, who only spent five mealtimes at home during his entire childhood.
    A Berliner in 1963 – but did John F Kennedy once admire Adolf Hitler?

    A Berliner in 1963 – but did John F Kennedy once admire Adolf Hitler?

    The young JFK praised 'superior' Nordic races during visits to Germany
    Banned Iranian director Mohammad Rasoulof to attend Cannes Film Festival 2013, his first public appearance since prison

    Banned Iranian director to attend Cannes Film Festival

    Mohammad Rasoulof to make his first public appearance since being imprisoned three years ago
    Seeing the larger picture: Inspiring images of space

    Seeing the larger picture: Inspiring images of space

    An exhibition explores images how photography has shaped astronomy
    Eat Spam and carry on: Wartime pamphlets could teach us a thing or two about healthy, thrifty eating

    Eat Spam and carry on

    Wartime pamphlets could teach us a thing or two about healthy, thrifty eating
    Facial hair: Cat beards and the purrrsuit of excellence

    Facial hair

    Cat beards and the purrrsuit of excellence
    The 10 Best salt and pepper sets

    The 10 Best salt and pepper sets

    Whether they're for everyday use or to make your dining table look just right, it's worth getting a stylish shaker...
    Ferran Soriano: Predicting success if Manchester City 'vision' is followed

    Ferran Soriano: Predicting success if Manchester City 'vision' is followed

    Chief executive says trophies will come if a 'core' of suitable players is in place
    Thomas Müller: We couldn't handle losing a Champions League Final again

    Thomas Müller: We couldn't handle losing a Champions League Final again

    The Bayern Munich forward tells Tim Rich his side have to shed chokers' tag after two recent final defeats
    Giro d'Italia: The Stelvio Pass - cycling's killer climb

    The Stelvio Pass - cycling's killer climb

    As the Giro d'Italia tackles the brutal climb, Simon Usborne takes on the snow and switchbacks – and soon realises what the fuss is about
    National archives: Edward VIII’s phone calls - and how MI5 bugged them

    Edward VIII’s phone calls - and how MI5 bugged them

    Newly unearthed papers reveal a shocking extra dimension to the constitutional crisis over monarch’s abdication
    Sent down at the Old Bailey: A tour of the world's most famous court

    Sent down at the Old Bailey

    A tour of the world's most famous court
    Hollywood's random acts of red-carpet kindness

    Hollywood's random acts of red-carpet kindness

    The Hangover actor Zach Galifianakis’s date for his movie premieres isn’t arm candy  – it’s his 87-year-old friend who he saved from homelessness
    British football scores an own goal

    British football scores an own goal

    Many managers barely survive a year in post. Martin Baker talks to experts who make a case for clubs using forensic business skills to find the best staff
    James Lawton: Sergio Garcia cracks as major fault line opens up again

    James Lawton

    Sergio Garcia cracks as major fault line opens up again